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Increased plasma triglyceride concentrations are an independent risk factor for cardiovascular disease. Numerous studies support a
reproducible genetic association between two minor haplotypes in the human apolipoprotein A5 gene (APOA5) and increased plasma triglyceride
concentrations. We thus sought to investigate the effects of these minor haplotypes (APOA5*2 and APOA5*3) on ApoAV plasma levels through
the precise insertion of single-copy APOA5 haplotypes at a targeted location (Hprt) in the mouse genome. While we found no difference in the
amount of human plasma ApoAV in mice containing the common APOA5*1 or minor APOA5*2 haplotype, the introduction of the single
APOA5*3-defining allele (19W) resulted in three fold lower ApoAV plasma levels, consistent with existing genetic association studies. These
results indicate that the S19W polymorphism is likely to be functional and explain the strong association of this variant with plasma triglycerides,
supporting the value of sensitive in vivo assays to define the functional nature of human haplotypes.
© 2007 Elsevier Inc. All rights reserved.Keywords: APOA5; Triglycerides; Cardiovascular disease; Haplotypes; Genetically engineered miceElevated lipid plasma levels are a significant risk factor for
stroke and coronary artery disease [1,2]. The apolipoprotein
gene cluster (APOA5/APOA4/APOC3/APOA1) on human
chromosome 11 (Fig. 1A) is one locus that has been genetically
linked to interindividual differences in plasma lipid levels [3,4].
Specifically, APOA5 is one member of this cluster that has been
strongly implicated in influencing plasma triglyceride levels in
both mice and humans [5]. Mice lacking Apoa5 have increased
plasma triglyceride concentrations, while mice overexpressing
human APOA5 exhibit decreased plasma triglyceride concen-
trations [5]. In humans, numerous studies in several different
ethnic populations have shown significant association between
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doi:10.1016/j.ygeno.2007.08.003elevated plasma triglyceride levels [5–12]. It is estimated that
53% of Hispanics, 35% of African-Americans, and 24% of
Caucasians carry at least one of these two minor haplotypes [6],
thus suggesting these haplotypes may be a common risk factor
for atherosclerosis in humans.
Recent in vitro studies have provided initial clues to the
possible functional alleles within these minor APOA5 haplo-
types. In humans, genetic studies showed that carriers of the
minor APOA5*2 haplotype [defined by the following nucleo-
tide changes: −1131T→C (rs662799), −3A→G (rs651821),
751G→T (rs2072560), and 1891T→C (rs2266788)] displayed
significantly lower ApoAV levels compared to the common
−1131T variant (152.4 ng/ml versus 200.8 ng/ml) as well as
elevated triglyceride levels (1.46 mmol/L versus 0.88 mmol/L)
[13]. However, subsequent in vitro functional studies of
−1131C and other APOA5*2 variants yielded no significant
alteration in transcription or translation in cell lines [14]. One
possible explanation for this observation is based on the strong
linkage disequilibrium of the APOA5*2 haplotype with three
neighboring APOC3 variants [15] (−482C→T, −455T→C,
Fig. 1. Generation of APOA5 haplotype mouse lines. (A) Apolipoprotein gene cluster on human chromosome 11. (B) APOA5 gene and locations of haplotype-
determining variants. (C) APOA5 haplotype constructs. (D) Recombination of the APOA5 haplotype constructs into a defective Hprt locus in the mouse.
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elevated plasma triglyceride concentrations in several human
populations [7,16–30]. Based on all these results, it remains
unclear whether the APOA5*2 haplotype contributes to
elevated plasma triglycerides through a cooperative effect of
all four APOA5 variants or in association with linked causal
APOC3 variants.
In contrast, the APOA5*3 haplotype associated with elevated
triglyceride concentrations is defined by a single coding variant
allele (rs3135506, changing 19S to 19W) and in vitro studies
revealed a functional consequence of this resulting amino acid
substitution [14]. Specifically, molecular modeling of the W19
variant predicted reduced translocation across the endoplasmic
reticulum, which was functionally supported through in vitro
studies indicating a two fold reduction in protein secretion in
comparison to the common 19S allele at this position [14]. In
addition, unlike APOA5*2, APOA5*3 showed no association
with any neighboring APOC3 SNP allele [15], suggesting that itis an isolated genetic variant that is functionally responsible for
the APOA5*3 haplotype association with elevated triglyceride
levels.
To assess further whether minor human APOA5 haplotypes by
themselves result in altered ApoAV plasma levels in vivo, we
inserted APOA5 haplotype constructs into mice through targeted
embryonic stem (ES) cell engineering. To circumvent the standard
mouse transgenic complications of variation in copy number and
integration sites, we inserted each haplotype construct into a
vector designed to rescue an ES cell line harboring a partially
defective hypoxanthine phosphoribosyltransferase gene (Hprt),
thereby allowing for appropriately targeted colonies to be
positively selected using hypoxanthine aminopterin thymidine
(HAT) medium [31]. Through these studies, we find that, while
APOA5*2 failed to result in any considerable change in ApoAV
plasma levels compared to APOA5*1, introduction of the W19
variant into the minor APOA5*2 haplotype significantly reduced
ApoAV plasma levels in vivo.
Fig. 2. APOA5 protein, mRNA and triglyceride levels in APOA5 haplotype
mice. (A) Human ApoAV plasma levels. (B) Human APOA5 liver mRNA levels
normalized to 18S RNA expression. (C) Total plasma triglyceride levels. Error
bars for all three charts indicate the standard error; N below the chart indicates
the number of mice assayed, followed by the mean ApoAV or triglyceride
plasma levels (mg/dl) and fold for mRNA levels and the standard error in each
experiment.
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Generation of APOA5 haplotype mouse lines
To generate each APOA5 haplotype construct, we electro-
nically identified two publicly available bacterial artificial
chromosome (BAC) clones that corresponded to haplotypes
APOA5*1 (BAC CTC-270C21) and APOA5*2 (BAC RP11-
442E11). From these BACs, we cloned an 11,360-bp fragment
(chromosome 11: 116,163,727–116,175,086; hg18) that corre-
sponds to the human APOA5 region (Fig. 1B; see Materials and
methods). The minor APOA5*3 haplotype was then constructed
through site-directed mutagenesis of the cloned APOA5*1
haplotype, creating a single change of S19 to 19W. In addition,
to ascertain the consequence of the 19W change we generated a
fourth hybrid haplotype of APOA5*2 and APOA5*3 through
similar site-directed mutagenesis of cloned haplotype
APOA5*2, changing c56C to c56G, hereafter referred to as
APOA*4 (Fig. 1C).
All four haplotypes were cloned into an Hprt replacement
vector [31] and each construct was independently electropo-
rated into a previously described E14TG2a Hprt-deficient 129
ES cell line (Fig. 1D) (see Materials and methods) [32].
Colonies resistant to HAT medium were screened using PCR
and Southern analysis (data not shown) to confirm proper
targeting and single integration events at the Hprt locus and
were subsequently injected into C57BL/6J blastocyst stage
embryos. The resulting male chimeras were bred to C57BL/6J
females to allow for detection of ES cell transmission based on
the 129 strain cell line-derived agouti coat color marker. Female
agouti mice positive for the transgene were bred to C57BL/6J
males to generate transgene-positive hemizygous males (Hprt is
located on the X chromosome). While haplotypes APOA5*1,
APOA5*2, and APOA5*4 were successfully transmitted
through the germ line, none of the resulting chimeric mice
from two separate APOA5*3 ES clones contained that
haplotype, despite repeated attempts. We thus limited our
analysis to the aforementioned mouse lines.
Plasma ApoAV levels are reduced for the haplotype APOA5*4
but not the APOA5*2 mouse line
To date, APOA5 expression has been detected only in the
liver, from which it is secreted into the plasma, functioning in
increasing lipolysis in the periphery as well as LDL clearance
by the liver. We thus sought to determine if ApoAV plasma
levels were altered due to the allelic variants found within their
respective haplotypes. We measured human ApoAV plasma
levels in male mice using a human-specific ApoAVantibody. As
a control, we found no detectable levels of human ApoAV in
littermates that were negative for the transgene (n=18). In
contrast, we detected an average ApoAV plasma level of
0.628 mg/dl in transgenic mice for the most common human
APOA5*1 haplotype (Fig. 2A). It is worth noting that these
levels are considerably lower than the average human levels that
are estimated to be 17.92±7.48 mg/dl [13]. This is likely the
result of the single-copy nature of the transgene as well as the
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the minor APOA5 haplotypes associated with increased
triglyceride levels in humans displayed altered ApoAV plasma
levels compared to APOA5*1. No significant difference (0.63
versus 0.60 mg/dl; p=0.810, t test) was observed between
APOA5*1 and APOA5*2 transgenic mice. In contrast,
APOA5*4, which contains a single S19 to W19 change within
APOA5*2, showed significantly lower ApoAV plasma levels
compared to APOA5*1 (0.17 versus 0.63 mg/dl; p=0.002,
t test) (Fig. 2A). Further studies of mRNA levels in liver tissue
from these three mouse lines revealed minimal differences in
APOA5 transcript levels, indicating that the decreased ApoAV
protein in APOA5*4 transgenic mice occurs posttranscription-
ally (Fig. 2B). Combined, these results indicate that while the
APOA5*2 variants do not have a significant effect on ApoAV
plasma levels, the W19 allele alone resulted in substantially
lower ApoAV levels.
Finally, we measured triglyceride levels in mice derived
from all APOA5 haplotype lines, observing no differences
between these cohorts (Fig. 2C). This was not unexpected since
the endogenous mouse locus for Apoa5 remains intact within
these Hprt-based targeted mice. Future studies aimed at
determining the effects of these transgenes with Apoa5-
deficient mice would assess directly the ability of these
haplotypes to recapitulate the triglyceride phenotypic differ-
ences found in humans. Nevertheless, the established role of
decreased ApoAV function leading to increased triglycerides in
knockout mice is consistent with human APOA5 minor
haplotypes leading to lower ApoAV protein levels, which in
turn raise triglycerides in plasma.
Discussion
Our goal in this study was to determine the in vivo effects of
APOA5 polymorphisms repeatedly associated with interindivi-
dual differences in plasma triglyceride concentrations. Using an
Hprt mouse targeting scheme, we created male mice, each
carrying a different single copy of a human APOA5 haplotype.
We were thus able to avoid the complexities of regular
transgenic mice in which multiple copies and different insertion
sites can significantly affect the expression of a transgene. In
addition, this transgenic scheme enabled the disconnection of
APOA5 from the neighboring APOC3 (as well as APOA4 and
APOA1), consequently revealing that only one of the two
minor haplotypes associated with increase triglycerides in
humans appears causative of this plasma phenotypic difference
across humans.
Previous in vitro functional studies on the majority of
variants defining APOA5*2 have suggested that the variants
within this haplotype are not functional [14]. However, these
studies were conducted within cell lines and were not able to
assess all haplotype-defining alleles in combination, but rather
studied each independently based on predictions on how they
may alter gene function. By inserting the entire APOA5*2
haplotype into the mouse, we find that these alleles combined
do not have a cooperative effect that might otherwise support
their causal role in the observed human genetic association withincreased triglycerides. These findings further suggest that this
APOA5*2 haplotype association may be explained due to its
strong linkage disequilibrium with previously characterized
triglyceride-elevating APOC3 alleles. It will be interesting in
future studies to determine the effects of APOC3 minor
haplotypes associated with increase plasma triglycerides levels
through similar in vivo studies.
We can strongly infer that the S19W variant is functional.
This is based on the observation that the single change of
APOA5*2 haplotype S19 to W19 resulted in a threefold
decrease in ApoAV plasma levels in vivo. This decrease is
consistent with previous functional studies that correlate this
change with a significant reduction in ApoAV secretion levels in
vitro [14]. The phenotypic outcome of such a reduction,
elevated plasma triglyceride levels, can be inferred from Apoa5
knockout mice. Apoa5-null homozygous mice have four times
higher plasma triglyceride levels than their wild-type littermates
[5], thus indicating that the expected phenotype of lower
ApoAV would be higher plasma triglyceride levels. In
conclusion, these results further support that individuals
carrying the APOA5*3 haplotype have a higher risk for elevated
plasma triglyceride levels directly through the S19W genetic
variant that defines this haplotype.
While this study was focused on APOA5-specific haplo-
types, the results are relevant to the increasing number of
genetic associations being identified in humans. These
statistical associations gain power through validation in
independent cohorts, but ultimately lack formal proof of their
causative nature. Through a combination of in vitro and in
vivo studies as described here it is anticipated that haplotypes
can be functionally linked to their associated human
phenotypes and provide an experimental means to define the
ultimate functional allele(s) within these stretches of human
DNA.Materials and methods
Cloning the APOA5 Hprt constructs
BACs 270C21 (APOA*1; GenBank AP001481) and 442e11 (APOA*2;
GenBank AC007707) were restriction digested sequentially with NotI and
BstEII and separated on a pulsed-field gel without ethidium bromide.
Electronically predicted 11.5-kb fragments were gel excised and purified using
aQiaEx II kit (Qiagen), blunt-end repaired using an EpiCenter CopyControl PCR
cloning kit (Epicentre), and ligated into a pCCI vector (Epicentre). Five-kilobase
HindIII fragments from both the APOA5*1 and the APOA5*2 clones in pCCI
were cloned into a pBS vector (Invitrogen) to facilitate the ease of site-directed
mutagenesis. In both vectors site-directed mutagenesis of the APOA5*3 variant
(c56C→G) was carried out using a Quickchange site-directed mutagenesis kit
(Stratagene). After mutagenesis clones were reverified by sequencing with
primers F1-AGAGGCCTCAGCTTTTCCAGGA, R1-GCGGATCCGAGCA-
GAGCAGA, R2-GCGGATCCGAGCAGAGCAGG, R3-TCTGGCTCTTCTT-
TCAGCGTTTTC, and R4-TCTGGCTCTTCTTTCAGCGTTTTG. Next, 5-kb
HindIII fragments were gel excised from pBS and ligated back into the
pCCI, thus generating haplotypes APOA5*3 and APOA5*4. We then cloned
these sequences into the pMP8NEB delta lacZ vector [31] (a kind gift from
Sarah K. Bronson) using NotI. To verify there were no mistakes in
orientation and nucleotide sequence of APOA5 and the haplotype-determining
alleles, we analyzed these vectors using restriction-enzyme-based analysis and
sequencing.
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All four APOA5 haplotypes within the pMP8NEB delta lacZ vectors were
linearized with NotI restriction enzyme and electroporated into an E14TG2a
Hprt-deficient 129 ES cell line [32]. Cells were grown on murine embryonic
fibroblasts in DMEM (Gibco) supplemented with 10% fetal bovine serum
(Hyclone), L-glutamine (Gibco), nonessential amino acids (Gibco), Hepes
(Gibco), β-mercaptoethanol (Sigma), penicillin/streptomycin (Gibco), and
ESGRO (Chemicon). Positive colonies were selected using HAT medium and
were screened by PCR using primers that spanned the mouse Hprt gene and
human AV gene junction. Sequences of primers were mHPRT F, 5′-TGA-
GTTCCTGCATTGAGCAACTGA-3′, and hApoAV R, 5′-TGAGATGCA-
GAGGGGACACTTGG-3′. For Southern blot 10 μg of genomic DNA was
digested with ScaI and the probe was synthesized using the following PCR
primer pair: 5′-TTATGGTACTGGCAGGGAGATTAGG-3′ and 5′-CAGAA-
CATCTTGAAACCCAGCATCC-3′. The resultant male chimeras were bred to
C57BL/6J females, and heterozygous females generated from these crosses were
mated with C57BL/6J males to generate transgene-positive hemizygous males.
Triglyceride measurements
All animals were fed standard chow diet and were analyzed between 2 and 4
months of age. Blood samples were collected after a 5-h fast by retro-orbital
bleeding using heparinized microhematocrit tubes. Total triglyceride concentra-
tions were measured using enzymatic methods (Sigma 337-A) in 96-well plates
using a Spectramax 250 (Molecular Devices).
APOA5 measurements
A pool of two monoclonal anti-human APOAV antibodies raised in mice
using recombinant protein was used at 10 μg/ml in 0.1 M PBS, pH 7.2, to coat
the wells of the microtiter plates at room temperature overnight. The wells were
washed twice with 0.1 M PBS and then saturated with 3% BSA/PBS for 1 h at
37°C. For quantitation, a pool of human plasma was calibrated and titrated using
ApoAV recombinant protein as a primary standard. Then, the pool of plasma was
used for the calibration curve. All dilutions were done in the blocking buffer (1%
BSA/PBS). One hundred microliters of the antigen solution was added to the
wells and incubated for 2 h at room temperature. The wells were washed four
times with PBS followed by the addition of an anti-ApoAV polyclonal antibody
(1:400) produced in goat using synthetic peptide and incubated for 2 h at 37°C.
Unbound antibody was removed by washing four times, and 100 μl of goat anti-
rabbit IgG-biotin conjugate diluted 1:20,000 (Sigma) was added to each well.
The plates were incubated for 1 h at 37°C and washed several times. Following
incubation with the biotinylated antibody, a solution of streptavidin-alkaline
phosphatase (1:500; Sigma) was added for 30 min at 37°C. Then, detection
using p-nitrophenyl phosphate substrate (Sigma) was performed in the dark at
room temperature and the absorbance at 405 nm was measured using a
microplate photometer (Dynex Technologies).
Real-time quantitative PCR
Total RNAwas extracted from liver tissue of adult mice using TRIzol reagent
(Invitrogen). Following reverse transcription with the SuperScript First-Strand
Synthesis System (Invitrogen), real-time PCR was performed using human
APOA5 gene-specific primers (5′-TCCTTGTCTGGGGAGCCTTGG-3′, and 5′-
CAACAGGCCACTTTCAAGGACTGA-3′), QuantumRNA Universal 18S
(Ambion), and the SYBR Green PCR Master Mix (Applied Biosystems) on a
7500 Fast Real-Time PCR System (Applied Biosystems). All procedures and
calculations were carried out according to the manufacturer's recommendations.Acknowledgments
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